Category: Healthcare Finance News

Telehealth is expected to drive $29 billion in healthcare services in 2020

Patients are largely on board with this paradigm shift, significantly increasing their engagement with the remote care platform.

Taskforce on Telehealth Policy releases final report on safeguarding virtual care

Its recommendations include lifting limitations on originating sites, allowing telehealth for various types of conditions and reinstating the HIPAA provisions temporarily lifted during the public health emergency.

CMS is now accepting grant applications from rural communities to improve healthcare

The amount of upfront and monthly payments will vary based on the level of risk that the ACO accepts in the Medicare Shared Savings Program.

Nonprofit hospitals’ liquidity supports the ability to repay CARES Act loans, says Fitch

Providers’ ratings are supported by ample liquidity, and the expectations are for a long-term volume recovery.

CMS proposes using only encounter data for Medicare Advantage risk adjustment and payment

The proposal is being released early for plans to better address estimating 2022 costs, in light of the uncertainty with the COVID-19 pandemic.

With price transparency an inevitability, hospitals need to start working toward compliance

Meeting the objectives of the final rule will be necessary to ensure compliance by January 1.

Kaiser Permanente launches ‘virtual-first’ health plan in Washington

The plan will make telehealth a foundational modality of care, with the option for patients to follow up with in-person visits if necessary.

541 ACOs in the Medicare Shared Savings Program saved Medicare $1.2 billion in 2019

Organizations such as the National Association of ACOs urge reforms to increase ACO growth and savings.

Artificial intelligence helps cut down on MRI no-shows

A predictive analytics model predicated on phone reminders cut missed appointments significantly, data showed.

AstraZeneca resumes Phase 3 COVID-19 vaccine trial in the U.K.

Following an independent investigation in a trial participant’s ‘unexplained illness,’ the company got the go-ahead to resume testing.